Drugs / d-methylphenidate
d-methylphenidate
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03292952 | Dec 2017 → May 2018 | attention deficit-hyperactivity disorder | Zevra Therapeutics | Completed | Met primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT00361387 | Jun 2006 → Jun 2007 | sarcoidosis | University of Cincinnati | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | d-methylphenidate | “KP415 (serdexmethylphenidate \[SDX\] Cl/ d-methylphenidate \[d-MPH\] HCl) oral capsule:” NCT03292952 ↗ |
| Known as | d-MPH | “We studied the effectiveness of dexmethylphenidate hydrochloride (d-MPH) in treating sarcoidosis-associated fatigue.” PMID 18263672 ↗ Feb 20081“KP415 (serdexmethylphenidate \[SDX\] Cl/ d-methylphenidate \[d-MPH\] HCl) oral capsule:” NCT03292952 ↗ |
| Known as | dexmethylphenidate hydrochloride | “We studied the effectiveness of dexmethylphenidate hydrochloride (d-MPH) in treating sarcoidosis-associated fatigue.” PMID 18263672 ↗ Feb 2008 |
| Route | Oral | “oral dosing for 8 weeks then cross over to placebo in random order” NCT00361387 ↗ |